Actinium Pharmaceuticals (STU:7AY1) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7AY1 Actinium Pharmaceuticals Inc STU:7AY1
50 GF Score
Price €0.90
GF Value €1.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals SpecialCharges?

Special Charges only applies to banks.

STU:7AY1
50GF Score
Actinium Pharmaceuticals Inc STU:7AY1
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Actinium Pharmaceuticals (STU:7AY1) Overvalued in 2026?

Based on GuruFocus' analysis, Actinium Pharmaceuticals stock appears to be undervalued. The current stock price of €0.90 is trading 20.4% below its estimated GF Value™ of €1.13. GuruFocus considers Actinium Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for STU:7AY1:

  • SpecialCharges:
  • GF Value™: €1.13 vs. price of €0.90 (20.4% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the STU:7AY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Actinium Pharmaceuticals Business Description

Other Exchanges ATNM:USA
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
50GF Score

Get the complete analysis for STU:7AY1

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.90
Price
€1.13
GF Value